Positive News SentimentPositive NewsNASDAQ:JYNT Joint (JYNT) Stock Price, News & Analysis $10.61 +0.15 (+1.43%) Closing price 04:00 PM EasternExtended Trading$10.62 +0.01 (+0.09%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Joint Stock (NASDAQ:JYNT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Joint alerts:Sign Up Key Stats Today's Range$10.33▼$10.7550-Day Range$10.17▼$12.1952-Week Range$9.58▼$13.47Volume230,786 shsAverage Volume60,567 shsMarket Capitalization$162.79 millionP/E RatioN/ADividend YieldN/APrice Target$16.33Consensus RatingBuy Company Overview The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona. Read More Joint Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreJYNT MarketRank™: Joint scored higher than 82% of companies evaluated by MarketBeat, and ranked 202nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingJoint has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJoint has only been the subject of 1 research reports in the past 90 days.Read more about Joint's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth381.82% Earnings GrowthEarnings for Joint are expected to grow by 381.82% in the coming year, from $0.11 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Joint is -32.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Joint is -32.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJoint has a P/B Ratio of 6.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Joint's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.91% of the float of Joint has been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Joint has recently increased by 7.37%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJoint does not currently pay a dividend.Dividend GrowthJoint does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.91% of the float of Joint has been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Joint has recently increased by 7.37%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment1.62 News SentimentJoint has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Joint this week, compared to 3 articles on an average week. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Joint insiders have bought more of their company's stock than they have sold. Specifically, they have bought $367,641.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders27.90% of the stock of Joint is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Joint's insider trading history. Receive JYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter. Email Address JYNT Stock News HeadlinesJoint (NASDAQ:JYNT) Director Acquires $107,000.00 in StockAugust 20 at 6:29 AM | insidertrades.comDo Options Traders Know Something About JYNT Stock We Don't?August 19 at 2:59 PM | msn.comThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening RIGHT NOW—this project is poised to see massive moves.... The smart money is already positioning.August 22 at 2:00 AM | Crypto 101 Media (Ad)Joint Corp’s Earnings Call: Mixed Outlook Amid Growth and ChallengesAugust 13, 2025 | msn.comThe Joint Corp. (NASDAQ:JYNT) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comThe Joint Corp. Delays Form 10-Q FilingAugust 12, 2025 | tipranks.comRakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery TechnologiesAugust 12, 2025 | globenewswire.comRoth MKM Sticks to Its Buy Rating for Joint (JYNT)August 12, 2025 | theglobeandmail.comSee More Headlines JYNT Stock Analysis - Frequently Asked Questions How have JYNT shares performed this year? Joint's stock was trading at $10.63 on January 1st, 2025. Since then, JYNT shares have decreased by 0.2% and is now trading at $10.61. How were Joint's earnings last quarter? The Joint Corp. (NASDAQ:JYNT) posted its earnings results on Thursday, August, 7th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $13.27 million for the quarter, compared to analyst estimates of $13.32 million. Joint had a negative net margin of 7.02% and a positive trailing twelve-month return on equity of 0.60%. Read the conference call transcript. Is Joint buying back stock? Joint's board initiated a share repurchase program on Thursday, June 5th 2025, which allows the company to buy back $5,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 2.7% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board of directors believes its shares are undervalued. When did Joint IPO? Joint (JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager. Who are Joint's major shareholders? Top institutional investors of Joint include JCP Investment Management LLC (3.12%), Topline Capital Management LLC (2.93%), Geode Capital Management LLC (2.26%) and O Brien Greene & Co. Inc (1.09%). Insiders that own company stock include Bandera Partners Llc and Christopher M Grandpre. View institutional ownership trends. How do I buy shares of Joint? Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Joint own? Based on aggregate information from My MarketBeat watchlists, some other companies that Joint investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/07/2025Today8/22/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - HMO Sub-IndustryTrading Current SymbolNASDAQ:JYNT CIK1612630 Webwww.thejoint.com Phone(480) 245-5960Fax480-513-7989Employees320Year FoundedN/APrice Target and Rating Average Price Target for Joint$16.33 High Price Target$18.00 Low Price Target$15.00 Potential Upside/Downside+52.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.33) Trailing P/E RatioN/A Forward P/E Ratio97.59 P/E GrowthN/ANet Income-$8.53 million Net Margins-7.02% Pretax Margin-1.40% Return on Equity0.60% Return on Assets0.16% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual Sales$53.45 million Price / Sales3.08 Cash Flow$0.68 per share Price / Cash Flow15.70 Book Value$1.52 per share Price / Book7.06Miscellaneous Outstanding Shares15,343,000Free Float11,062,000Market Cap$164.71 million OptionableOptionable Beta1.53 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:JYNT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Joint Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Joint With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.